Metastatic Breast Cancer Clinical Trials

A listing of 71 Metastatic Breast Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Metastatic Breast Cancer

1 - 12 of 71

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 71 active clinical trials seeking participants for Metastatic Breast Cancer research studies. The states with the highest number of trials for Metastatic Breast Cancer participants are Texas, California, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

Featured Trial

High Triglyceride Clinical Research Study

Recruiting

Living with high triglycerides? See if our clinical study is right for you.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.

Conditions:

High Triglycerides

High Triglyceride Level

Hypertriglyceridemia

Elevated Triglycerides

Triglycerides High

Learn More

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357

Recruiting

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (T-DXd) or with trastuzumab emtansine (T-DM1... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/20/2025

Locations: Valkyrie Clinical Trials, Los Angeles, California +44 locations

Valkyrie Clinical Trials, Los Angeles, California

University of California Irvine, Orange, California

Sharp Memorial Hospital, San Diego, California

Yale University School of Medicine, New Haven, Connecticut

University of Iowa Hospitals and Clinics, Iowa City, Iowa

The Methodist Hospital Research Institute, Houston, Texas

Virginia Cancer Specialists, PC, Fairfax, Virginia

Fred Hutchinson Cancer Research Center, Seattle, Washington

UZ Leuven, Leuven, Not set

Centre Hospitalier de l'Ardenne, Libramont-Chevigny, Not set

Centre Hospitalier Universitaire de Liège, Liege, Not set

CHU UCL Namur - Site De Sainte-Elisabeth, Namur, Not set

Jilin Province Cancer Hospital, Changchun, Not set

The First Hospital of Jilin University, Changchun, Not set

Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Not set

Harbin Medical University Cancer Hospital, Harbin, Not set

Jiangsu Province Hospital, Nanjing, Not set

Fudan University Shanghai Cancer Center, Shanghai, Not set

Tianjin Cancer Hospital, Tianjin, Not set

Henan Cancer Hospital, Zhengzhou, Not set

Istituto Di Candiolo, Candiolo (TO), Not set

Az.Osp. Universitaria "Ospedali Riuniti", Foggia, Not set

Istituto Scientifico Romagnolo, Meldola (fc), Not set

IRCCS San Raffaele, Milano, Not set

Istituto Europeo di Oncologia, Milano, Not set

Istituto Nazionale IRCCS Tumori Fondazione Pascale, Napoli, Not set

Istituto Clinico Humanitas, Rozzano, Not set

Aichi Cancer Center Hospital, Aichi, Nagoya, Not set

Hakuaikai Sagara Hospital, Kagoshima-shi, Not set

Tokai University Hospital, Kanagawa, Isehara, Not set

Kanagawa Cancer Center, Kanagawa, Yokohama, Not set

National Cancer Center Hospital East, Kashiwa-shi, Not set

Kyoto University Hospital, Kyoto, Kyoto, Not set

Osaka International Cancer Institute, Osaka-shi, Not set

Hospital Teresa Herrera, A Coruña, Not set

Hospital del Mar, Barcelona, Not set

Hospital Vall d'Hebron, Barcelona, Not set

Hospital Clínic de Barcelona, Barcelona, Not set

Hospital General Universitario Gregorio Marañón, Madrid, Not set

Clínica Universidad de Navarra - Madrid, Madrid, Not set

Servicio de Oncología, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital La Paz, Madrid, Not set

CIO Clara Campal, Madrid, Not set

Hospital Virgen Macarena, Sevilla, Not set

Conditions: Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

Learn More ›

A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

NCT06157892

Recruiting

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are f... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/19/2025

Locations: Arizona Cancer Center / University of Arizona, Tucson, Arizona +38 locations

Arizona Cancer Center / University of Arizona, Tucson, Arizona

Chao Family Comprehensive Cancer Center University of California Irvine, Orange, California

University of California, San Francisco | HDFCCC - Hematopoietic Malignancies, San Francisco, California

UCLA Department of Medicine - Hematology & Oncology, Santa Monica, California

Colorado West Healthcare, dba Grand Valley Oncology, Grand Junction, Colorado

Praxair Cancer Center / Danbury Hospital, Danbury, Connecticut

The Whittingham Cancer Center / Norwalk Hospital, Norwalk, Connecticut

MedStar Georgetown University Hospital, Washington, District of Columbia

Massachusetts General Hospital, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Saint Luke's Cancer Institute LLC, Kansas City, Missouri

Washington University in St Louis, Saint Louis, Missouri

Renown Oncology, Reno, Nevada

San Juan Oncology Associates, Farmington, New Mexico

Memorial Sloan Kettering Cancer Center, New York, New York

Zangmeister Cancer Center, Columbus, Ohio

Saint Francis Hospital / Bon Secours - South Carolina, Greenville, South Carolina

SCRI Oncology Partners, Nashville, Tennessee

Carbone Cancer Center / University of Wisconsin, Madison, Wisconsin

Peninsula and South East Oncology, Frankston, Other

BC Cancer Kelowna, Kelowna, British Columbia

Ottawa Hospital Cancer Centre, Ottawa, Ontario

Sunnybrook Health Sciences Centre, Toronto, Ontario

University Health Network, Princess Margaret Hospital, Toronto, Ontario

Istituto Europeo di Oncologia, Milano, Other

Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Other

Chungbuk National University Hospital, Cheongju-si, Other

Gachon University Gil Medical Center, Incheon, Other

Seoul National University Bundang Hospital, Seongnam-si, Other

Severance Hospital, Yonsei University Health System, Seoul, Other

St. Vincent's Hospital, The Catholic University of Korea, Suwon-si, Other

Samsung Medical Center, Seoul, Not set

Hospital Universitari Vall d'Hebron, Barcelona, Other

L'Institut Catala d'Oncologia, Barcelona, Other

START Madrid-CIOCC_Hospital HM Sanchinarro, Madrid, Other

Hospital Clinico Universitario de Valencia, Valencia, Other

St Bartholomew's Hospital, London, Other

The Royal Marsden NHS Foundation Trust (RM), London, Other

Royal Marsden Hospital Sutton, Surrey, Other

Conditions: Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer

Learn More ›

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

NCT03808337

Recruiting

This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/19/2025

Locations: Natera, Inc. (Data and Specimen Analysis Only), San Carlos, California +11 locations

Conditions: Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma

Learn More ›

Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

NCT05573126

Recruiting

The aim of this study is to identify the optimal dose for Vosilasarm (EP0062) as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

02/19/2025

Locations: Yale School of Medicine, New Haven, Connecticut +13 locations

Conditions: Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer

Learn More ›

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

NCT04115306

Recruiting

The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/18/2025

Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +7 locations

Conditions: Metastatic Breast Cancer

Learn More ›

Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

NCT04990921

Recruiting

This is a phase 2, open-label, single-arm trial designed to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) in combination with pembrolizumab following disease progression after two prior lines of standard therapy in unresectable metastatic stage IV breast cancer

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

02/18/2025

Locations: James Graham Brown Cancer Center, Louisville, Kentucky

Conditions: Metastatic Breast Cancer

Learn More ›

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

NCT05563220

Recruiting

This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/17/2025

Locations: Dothan Hematology and Oncology, Dothan, Alabama +115 locations

Dothan Hematology and Oncology, Dothan, Alabama

Mayo Clinic - Arizona, Phoenix, Arizona

Highlands Oncology Group, Springdale, Arkansas

OPN Healthcare (Arcadia Location), Arcadia, California

Glendale Adventist, Glendale, California

OPN Healthcare (Los Alamitos Location), Los Alamitos, California

Cedars Sinai, Los Angeles, California

UCLA UCLA Hem/Onc - Clinical Research Unit, Los Angeles, California

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

TOI Clinical Research, Whittier, California

Rocky Mountain Cancer Centers, Lone Tree, Colorado

Yale School Of Medicine - Smilow Cancer Hospital - Breast Center, New Haven, Connecticut

George Washington Cancer Center, Washington, District of Columbia

Advent Health (Florida Hospital) - Altamonte Springs, Altamonte Springs, Florida

Mayo Clinic - Jacksonville, Jacksonville, Florida

Ocala Oncology, Ocala, Florida

Northside Hospital Atlanta Cancer Care, Cumming, Georgia

Northwestern Feinberg Scholl of Medicine Prentice Women's Hospital, Chicago, Illinois

Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana

MD Alliance for Multispecialty Research, LLC, Merriam, Kansas

New England Cancer Specialists, Scarborough, Maine

Johns Hopkins School of Medicine, Baltimore, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Minnesota Oncology Hematology, Minneapolis, Minnesota

Mayo Clinic - Rochester, Rochester, Minnesota

Washington University School of Medicine in St. Louis, Saint Louis, Missouri

Astera Cancer Care, East Brunswick, New Jersey

Summit Medical Group, Florham Park, New Jersey

Cooperman Barnabas Medical Center, New Brunswick, New Jersey

NYU Langone Health, New York, New York

New York Cancer and Blood Specialists, Port Jefferson Station, New York

W&IH of RI Breast Health Center of Women and Infants Hospital of Rhode Island, Providence, Rhode Island

Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

MD Anderson Cancer Center Texas, Houston, Texas

UT Health San Antonio, San Antonio, Texas

Inova Schar Cancer Institute, Fairfax, Virginia

Virginia Cancer Specialists, Fairfax, Virginia

Virginia Oncology Associates, Norfolk, Virginia

Cancer Care Northwest, Spokane Valley, Washington

Northwest Medical Specialties (Nwms) - Puyallup - Medical Oncology (Rainier Hematology-Oncology)/Exigent Research Network; LLC, Tacoma, Washington

University of WI - Carbone Cancer Center (Phase II only), Madison, Wisconsin

Centro Medico Austral, Buenos Aires, Not set

Hospital Britanico De Buenos Aires, Buenos Aires, Not set

Cemaic - Centro De Especialidades Medicas Ambulatorias E Investigacion Clinica, Cordoba, Not set

Centro Oncologico Riojano Integral (Cori), La Rioja, Not set

Macquarie University, Sydney, Not set

Institut Jules Bordet, Anderlecht, Not set

Grand Hôpital de Charleroi - Site Notre Dame, Charleroi, Not set

Universitaire Ziekenhuizen (Uz) Leuven - Campus Gasthuisberg - Multidisciplinair Borstcentrum (Multidisciplinary Breast Center) (Mbc), Leuven, Not set

Algemeen Ziekenhuis Nikolaas; VITAZ; Oncologie Klinisch Studiecentrum, Sint-Niklaas, Not set

ACCG - Hospital Araujo Jorge, Goiania, Not set

Clinica Neoplasias Litoral, Itajai, Not set

Hospital Sao Lucas da PUCRS, Porto Alegre, Not set

Centro Gaucho Integrado de Oncologia; Hematologia; Ensino e Pesquisa - Hospital Mae de Deus/AESC, Porto Alegre, Not set

Hospital Sirio-Libanes (HSL) - Centro De Oncologia - Sao Paulo, Sao Paulo, Not set

Nemocnice Horovice Hospital, Hořovice, Not set

Fakultni Nemocnice Olomouc, Olomouc, Not set

Centre Hospitalier Lyon SUD- HCL, Lyon, Not set

Centre de Cancérologie du Grand Montpellier, Montpellier, Not set

Centre de Cancérologie du Grand Montpellier, Rouen, Not set

Centre Hospitalier Universitaire (Chu) De Toulouse - Institut Universitaire Du Cancer De Toulouse-Oncopole (Iuct-Oncopole) (Institut Claudius Regaud), Toulouse, Not set

Institut Gustave-Roussy-Umr 981, Villejuif, Not set

Universitaetsklinikum Mannheim, Mannheim, Baden-Wuerttemberg

Technischen Universitaet Muenchen (TUM), Klinikum Rechts der Isar, Muenchen, Bayern

Universitatskinikum Carl Gustav Carus Dresden, Dresden, Sachsen

Marienhospital Bottrop, Bottrop, Not set

Universitatskinikum Carl Gustav Carus Dresden, Dresden, Not set

Kliniken Essen-Mitte (KEM), Essen, Not set

Gesundheit Nordhessen Klinikum Kassel, Kassel, Not set

Universitaetsklinikum Tuebingen, Tübingen, Not set

Semmelweis Egyetem Klinikai Kozpont - Onkologiai Intezet, Budapest, Not set

Orszagos Onkologiai Intezet, Budapest, Not set

Samson Assuta Ashdod University Hospital - The Institute of Oncology, Ashdod, Not set

Rambam Heath, Haifa, Not set

Shaare Zedek Medical Center, Jerusalem, Not set

Davidoff Rabin Medical Center, Petah Tikva, Not set

Sheba Medical Center; Center Israel, Ramat Gan, Not set

ASST degli Spedali Civili di Brescia, Brescia, Not set

Azienda Ospedaliera "Istituti Ospitalieri" Di Cremona, Cremona, Not set

Istituto Nazionale Tumori "Fondazione PASCALE", Napoli, Not set

Azienda Ospedaliero-Universitaria Pisana, Pisa, Not set

Ospedale Infermi di Rimini - Azienda Unita Sanitaria Locale Della Romagna, Rimini, Not set

Seoul National University Bundang Hospital, Seongnam-si, Not set

Asan Medical Center, Seoul, Not set

Gangnam Severance Hospital, Seoul, Not set

The Catholic University of Korea - Seoul St. Mary's Hospital, Seoul, Not set

Korea University Anam Hospital, Seoul, Not set

Ulsan University Hospital, Ulsan, Not set

Centre Hospitalier De L'Ardenne, Libramont, Not set

Klinika Onkologii; Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy, Warszawa, Mazowieckie

Przychodnia Lekarska "Komed" Roman Karaszewski, Konin, Not set

Med-Polonia Sp. Z o.o., Poznań, Not set

Instytut Centrum Zdrowia Matki Polki, Łódź, Not set

Complejo Hospitalario Universitario A Coruna, A Coruña, Not set

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Hospital Clinic Barcelona, Barcelona, Not set

Hospital General Universitario Gregorio Maranon, Madrid, Not set

IOB Madrd Institute of Oncology Hospital Beata Maria Ana de Jesus, Madrid, Not set

Hospital Clinico San Carlos, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario Virgen de la Victoria, Malaga, Not set

NEXT Madrid, Pozuelo de Alarcon, Not set

Fundacion Instituto Valeciano De Oncologia, Valencia, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Hospital Arnau De Vilanova, Valencia, Not set

Abdurrahman Yurtaslan Oncology Hospital, Ankara, Not set

Ankara Bilkent City Hospital, Bilkent Campus, Universiteler Mh. (old: Ankara Yildirim Beyazit Universitesi), Ankara, Not set

The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Not set

Liverpool Hospital, Liverpool, Not set

North Middlesex University Hospital, London, Not set

Sarah Cannon Research Institute UK; Ltd, London, Not set

University College London Hospitals NHS Foundation Trust; The London Clinic - Main Hospital, London, Not set

Conditions: Breast Cancer, Metastatic Breast Cancer

Learn More ›

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

NCT06756932

Recruiting

The purpose of this study is to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/14/2025

Locations: Hoag Memorial Presbyterian, Newport, California +14 locations

Conditions: Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer

Learn More ›

A Study of Alisertib in Combination with Endocrine Therapy in Patients with HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

NCT06369285

Recruiting

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is a... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/14/2025

Locations: Alabama Oncology, Birmingham, Alabama +21 locations

Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer

Learn More ›

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT06120283

Recruiting

This is a dose escalation and dose expansion study to compare how well BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with either fulvestrant or letrozole in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/14/2025

Locations: Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado +64 locations

Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado

Florida Cancer Specialists and Research Institute, Lake Mary, Florida

Karmanos Cancer Institute, Detroit, Michigan

Washington University School of Medicine, Saint Louis, Missouri

Duke Cancer Center, Durham, North Carolina

James Cancer Hospital and Solove Research Institute, Columbus, Ohio

Scri Oncology Partners, Nashville, Tennessee

The University of Texas Md Anderson Cancer Center, Houston, Texas

Next Dallas, Irving, Texas

Next Oncology, San Antonio, Texas

Blacktown Cancer and Haematology Centre, Blacktown, New South Wales

Southern Highlands Private Hospital, Bowral, New South Wales

Concord Repatriation General Hospital, Concord, New South Wales

Macquarie University, North Ryde, New South Wales

Townsville University Hospital, Douglas, Queensland

Genesiscare St Andrews, Adelaide, South Australia

Austin Health, Heidelberg, Victoria

Peter Maccallum Cancer Centre, Melbourne, Victoria

Fundacao Pio Xii Hospital de Amor de Barretos, Barretos, Not set

Hospital Sirio Libanes Brasilia, Brasilia, Not set

Centro de Pesquisas Oncologicas Cepon, Florianopolis, Not set

Liga Norte Riograndene Contra O Cancer, Natal, Not set

Fundacao Universidade de Caxias Do Sul Instituto de Pesquisas Em Saude, Petropolis, Not set

Hospital Sao Lucas Da Pucrs Uniao Brasileira de Educacao E Assistencia, Porto Algre, Not set

Instituto Nacional de Cancer, Rio de Janeiro, Not set

Instituto Dor de Pesquisa E Ensino Hospital Sao Rafael, Salvador, Not set

Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira, Sao Paulo, Not set

Clinica de Pesquisa E Centro de Estudos Em Oncologia Ginecologica E Mamaria, Sao Paulo, Not set

Hospital Israelita Albert Einstein, Sao Paulo, Not set

Beijing Cancer Hospital, Beijing, Beijing

Fujian Cancer Hospital, Fuzhou, Fujian

Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi

Liaoning Cancer Hospital and Institute, Shenyang, Liaoning

Fudan University Shanghai Cancer Centerpudong, Shanghai, Shanghai

Centre de Lutte Contre Le Cancer Institut Bergonie, Bordeaux, Not set

Centre Francois Baclesse, Caen Cedex, Not set

Centre Oscar Lambret, Lille, Not set

Institut Paoli Calmettes, Marseille, Not set

Institut Curie, Paris, Not set

Centre Eugene Marquis, Rennes, Not set

Institut de Cancerologie de Louest, St Herblain, Not set

Institut Gustave Roussy, Villejuif, Not set

Nagoya University Hospital, Nagoya, Aichi

National Cancer Center Hospital East, Kashiwa, Chiba

Shizuoka Cancer Center, Suntogun, Shizuoka

Seoul National University Bundang Hospital, Seongnamsi, Gyeonggi-do

Korea University Anam Hospital, Seoul, Gyeonggi-do

Gachon University Gil Medical Center, Incheon, Incheon Gwang'yeogsi

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Severance Hospital Yonsei University Health System, Seoul, Seoul Teugbyeolsi

Asan Medical Center, Seoul, Seoul Teugbyeolsi

Samsung Medical Center, Seoul, Seoul Teugbyeolsi

The Catholic University of Korea, Seoul St Marys Hospital, Seoul, Seoul Teugbyeolsi

Pulau Pinang Hospital, Georgetown, Not set

University Malaya Medical Centre, Kuala Lumpur, Not set

Sarawak General Hospital, Kuching, Not set

National Cancer Institute (Institut Kanser Negara), Putrajaya, Not set

The Institute of Oncology, Arensia Exploratory Medicine, Chisinau, Not set

Harbour Cancer and Wellness, Auckland, Not set

Nzcr Christchurch, Christchurch, Not set

Siriraj Hospital, Bangkok, Not set

Banphaeo General Hospital, Banphaeo, Not set

Srinagarind Hospital (Khon Kaen University), Muang, Not set

Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer

Learn More ›

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239

Recruiting

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/13/2025

Locations: Banner Health MD Anderson AZ, Gilbert, Arizona +157 locations

Banner Health MD Anderson AZ, Gilbert, Arizona

Disney Family Cancer Center, Burbank, California

Ellison Institute of Technology, Los Angeles, California

Georgetown Uni Hospital, Washington, District of Columbia

Medstar Research Institute, Hyattsville, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

Henry Ford Hospital, Detroit, Michigan

Renown Regional Medical Center, Reno, Nevada

Hackensack University Medical Center, Hackensack, New Jersey

Atrium Health, Charlotte, North Carolina

Hightower Clinical, Oklahoma City, Oklahoma

Renovatio Clinical - El Paso, El Paso, Texas

JPS Health Network, Fort Worth, Texas

Lumi Research, Kingwood, Texas

Renovatio Clinical, The Woodlands, Texas

Kadlec Clinic Hematology and Oncology, Kennewick, Washington

Swedish Medical Center, Seattle, Washington

Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Not set

Centro Oncologico Korben, Ciudad Autonoma Buenos Aires, Not set

Instituto de Oncología de Rosario, Rosario, Not set

Hospital Provincial del Centenario, Rosario, Not set

CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica, San Juan, Not set

Clínica Viedma, Viedma Rio Negro, Not set

Blacktown Hospital, Blacktown, New South Wales

Kinghorn Cancer Centre, Darlinghurst, New South Wales

Gosford Hospital, Gosford, New South Wales

University of the Sunshine Coast, Sippy Downs, Queensland

Monash Health, Clayton, Victoria

Sir Charles Gairdner Hospital, Perth, Western Australia

Cliniques Universitaires St-Luc, Bruxelles, Not set

GHdC Site Les Viviers, Charleroi, Not set

Jessa Zkh (Campus Virga Jesse), Hasselt, Not set

Clinique Ste-Elisabeth, Namur, Not set

Hospital Sao Rafael - HSR, Salvador, Bahia

Crio - Centro Regional Integrado de Oncologia, Fortaleza, Ceará

Hospital Araujo Jorge, Goiania, Goiás

Hospital do Câncer de Londrina, Londrina, Paraná

Hospital do Cancer de Pernambuco - HCP, Recife, Pernambuco

Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul

Hospital Sao Lucas - PUCRS, Porto Alegre, Rio Grande Do Sul

Hospital de Amor Amazônia, Porto Velho, Rondônia

Hospital de Cancer de Barretos, Barretos, São Paulo

Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, São Paulo

Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paulo, São Paulo

Arthur J.E. Child Comprehensive Cancer Center-Calgary, Calgary, Alberta

The Moncton Hospital, Moncton, New Brunswick

Eastern Health - General Hospital, St. John's, Newfoundland and Labrador

Sunnybrook Health Sciences Centre, Toronto, Ontario

Centre Hospitalier de l?Université de Montréal (CHUM), Montreal, Quebec

Jewish General Hospital, Montreal, Quebec

Hôpital du Sacré-Coeur de Montreal, Montreal, Quebec

Hopital du Saint Sacrement, Quebec City, Quebec

Allan Blair Cancer Center, Regina, Saskatchewan

Affiliated Hospital of Hebei University, Baoding, Not set

Beijing Cancer Hospital, Beijing, Not set

The First Hospital of Jilin University, Changchun City, Not set

Sichuan Provincial Cancer Hospital, Chengdu, Not set

Sichuan Provincial People's Hospital, Chengdu, Not set

Fujian Cancer Hospital, Fuzhou, Not set

Zhejiang Cancer Hospital, Hangzhou City, Not set

Harbin Medical University Tumor Hospital, Harbin, Not set

Shandong Cancer Hospital, Jinan, Not set

The First Affiliated Hospital to Henan University of Science and Technology, Luoyang, Not set

The Second Affiliated Hospital to Nanchang University, Nanchang, Not set

Guangxi Cancer Hospital of Guangxi Medical University, Nanning, Not set

Shantou Center Hospital, Shantou City, Not set

Tianjin Cancer Hospital, Tianjin, Not set

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, Not set

Hubei Cancer Hospital, Wuhan, Not set

Clinica De La Costa, Barranquilla, Not set

Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Bogota, D.C., Not set

Oncomedica S.A., Monteria, Not set

Tampere University Hospital, Tampere, Not set

Turku Uni Central Hospital, Turku, Not set

Institut Sainte Catherine, Avignon, Not set

Centre Hospitalier de La Cote Basque, Bayonne, Not set

Polyclinique Bordeaux Nord Aquitaine, Bordeaux, Not set

Klinikum St. Marien, Amberg, Not set

Marienhospital Bottrop gGmbH, Bottrop, Not set

Gynonco Düsseldorf, MVZ Medical Center GmbH, Düsseldorf, Not set

Frauenarztpraxis Dr. Apel, Dr. Kolpin, Erfurt, Not set

Praxis für Interdisziplinäre Onkologie und Hämatologie GbR, Freiburg, Not set

Klinik & Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Innenstadt, München, Not set

Caritas Klinik St. Theresia -Frauenklinik Brustzentrum, Saarbruecken, Not set

Gynäkologie Kompetenzzentrum, Stralsund, Not set

Queen Mary Hospital, Hong Kong, Not set

Tuen Mun Hospital, Hong Kong, Not set

Max Super Speciality Hospital, NEW Delhi Delhi, Delhi

Sunshine Global Hospital (A unit of Baroda Medicare Pvt Ltd), Surat CITY, Gujarat

Artemis Hospital, Gurugram, Haryana

Tata Medical Center, Kolkata, WEST Bengal

I.R.S.T Srl IRCCS, Meldola, Emilia-Romagna

Ospedale San Giovanni Addolorata, Roma, Lazio

Ospedale San Raffaele, Milano, Lombardia

Irccs Istituto Nazionale Dei Tumori (Int), Milano, Lombardia

Irccs Istituto Europeo Di Oncologia (IEO), Milano, Lombardia

Ospedale San Gerardo, Monza, Lombardia

A.O.U. Maggiore della Carità, Novara, Piemonte

Casa di Cura La Maddalena, Palermo, Sicilia

Ospedale Santa Maria Annunziata, Bagno a Ripoli, Toscana

"Azienda Ospedaliera Universitaria Integrata Verona Ospedale Borgo Trento", Verona, Veneto

King Hussein Cancer Center, Amman, Not set

University of Nairobi - Institute of Tropical and Infectious Diseases, Nairobi, Not set

National Cancer Center, Goyang-si, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Gangnam Severance Hospital, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Seoul St Mary's Hospital, Seoul, Not set

Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco

OncoMed, Ciudad de México, Mexico CITY (federal District)

Centro Oncológico Hematológico Roma, Mexico City, Mexico CITY (federal District)

Hospital Universitario, Monterrey, Nuevo LEON

CENEIT Oncologicos, Mexico City, Not set

Sultan Qaboos Comprehensive Cancer Care & Research Center, Muscat, Not set

Centrum Onkologii im. Prof. Franciszka ?ukaszczyka, Bydgoszcz, Not set

Uniwersyteckie Centrum Kliniczne, Gda?sk, Not set

Szpital Morski im.PCK, Gdynia, Not set

Narodowy Instytut Onkologii Odzia? w Gliwicach, Gliwice, Not set

Przychodnia Lekarska KOMED, Roman Karaszewski, Konin, Not set

Szpital Wojewódzki im. Miko?aja Kopernika, Koszalin, Not set

Wielkopolskie Centrum Onkologii im. Marii Sk?odowskiej-Curie, Pozna?, Not set

Centrum Onkologii Instytut im.M. Sklodowskiej-Curie, Warszawa, Not set

National University Hospital, Singapore, Not set

National Cancer Centre, Singapore, Not set

Icon Cancer Centre Farrer Park, Singapore, Not set

Tan Tock Seng Hospital, Singapore, Not set

Hopelands Cancer Centre, Hilton, Not set

Charlotte Maxeke Academic Hospital, Johannesburg, Not set

Medical Oncology Centre of Rosebank, Johannesburg, Not set

Limpopo Cancer Research Institute, Polokwane, Not set

Steve Biko Academic Hospital, Pretoria, Not set

Chris Hani Baragwanath Clinical Trial Site, Soweto, Not set

Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, LA Coruna

Hospital Universitari Dexeus - Grupo Quironsalud, Barcelona, Not set

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Hospital General Universitario Gregorio Marañon, Madrid, Not set

Hospital Ramon y Cajal, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Clinico Universitario Virgen de la Victoria, Malaga, Not set

Hospital Universitario Virgen Macarena, Sevilla, Not set

National Taiwan Uni Hospital, Taipei, Not set

Tri-Service General Hospital, Taipei, Not set

Chang Gung Memorial Hospital-Linkou, Taoyuan County, Not set

Abderrahmen Mami Hospital, Ariana, Not set

Gazi University Medical Faculty, Ankara, Not set

Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji, Bakirkoy / Istanbul, Not set

Dicle University Faculty of Medicine, Diyarbakir, Not set

Medipol Mega Üniversite Hastanesi Göztepe, Istanbul, Not set

Katip Celebi University Ataturk Training and Research Hospital, Izmir, Not set

Medical Park Seyhan Hospital, Seyhan, Not set

Hacettepe Uni Medical Faculty Hospital, Sihhiye/Ankara, Not set

Blackpool Victoria Hospital, Blackpool, Not set

Colchester General Hospital, Colchester, Essex, Not set

Mount Vernon Hospital, Northwood, Not set

Nottingham City Hospital, Nottingham, Not set

Churchill Hospital, Oxford, Not set

Conditions: Metastatic Breast Cancer

Learn More ›

TReatment of ADC-Refractory Breast CancEr with Dato-DXd or T-DXd: TRADE DXd

NCT06533826

Recruiting

The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-low metastatic breast cancer. The names of the study drugs involved in this study are: * Datopotamab deruxtecan (a type of antibody drug conjugate) * Trastuzumab deruxtecan (a type of antibody drug conjugate)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/12/2025

Locations: Dana-Farber Cancer Institute, Boston, Massachusetts

Conditions: Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer

Learn More ›

1 - 12 of 71